Figure. 5.

HSR promotes the angiogenic and myocardial repair potential of CHD derived hCDCs. CEL or HS treatment of CHD derived CDCs increased selective cytokine secretion as determined by ELISA on conditioned media after 72 hours of CEL or HS treatment. (A–E) In the presence of CEL or HS, CHD derived CDCs showed increased secretion of SDF-1α (*P=0.022), VEGF-1A (*P=0.04), PGDFB (*P=0.03), IL-6 (*P=0.017) and FGF-2 (*P=0.027), (F–J) but not LIF, SCF, IGF1, HGF, LIF and IL-1. HSR enhanced the pro-angiogenic capacity of CHD derived CDCs. (K) Representative images (left) and quantification of total tube length (right) of HUVECs 8 hours after plating on matrix coated wells with IMDM or condition media from HUVECs, CM-CHD, CM-CDCs-CEL and CM-CDCs-HS (scale bar = 140µm). (L) CEL treated CHD derived CDCs outperformed non-treated CHD derived CDCs in preserving left ventricle function in the infarction myocardium. Treated or untreated CDCs were injected into the infarcted myocardium of immunodeficient rats and function was assessed by echocardiography at 7 days and at 28 days (M) Immunofluorescence (left) demonstrated increased preservation/formation of arterioles (α-SMA, green) after HS or CEL treatment of CHD derived CDCs (right, **P<0.01). Data are analyzed by 2-Way ANOVA followed by Benferroni’s analysis or one –way ANOVA (non-parametric, Kruskal-Wallis test) followed by Dunns analysis. Data are presented as mean ± SEM.